Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis.
BACKGROUND
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease without an effective treatment, characterized by pain during bladder filling. Most nociceptive bladder afferents course in the trigone.


OBJECTIVE
To evaluate efficacy and tolerability of trigonal injection of botulinum toxin A (BoNTA) in patients with BPS/IC. Urine concentration of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) were also evaluated.


METHODS
Women with refractory BPS/IC were included in an open, exploratory study.


METHODS
Under sedation, 100 U of BoNTA (Botox) were injected in 10 trigonal sites (10 U per 1 ml saline). Retreatment was allowed 3 mo after injection.


METHODS
Pain, urinary frequency, O'Leary-Sant score (OSS), quality of life, (QoL), and urodynamic testing at 1 and 3 mo and every 3 mo thereafter. Urine NGF and BDNF were assessed at the same points. Patients who were retreated were evaluated every 3 mo.


CONCLUSIONS
All patients reported subjective improvement at 1- and 3-mo follow-up. Pain, daytime and nighttime voiding frequency, OSS, and QoL improved significantly. Bladder volume to first pain and maximal cystometric capacity more than doubled. Treatment remained effective in >50% of the patients for 9 mo. Retreatment was also effective in all cases, with similar duration. A significant, transient reduction in urinary NGF and BDNF was observed. No cases of voiding dysfunction occurred. The low number of patients and the lack of a placebo arm are obvious limitations of this study.


CONCLUSIONS
Trigonal injection of BoNTA is a safe and effective treatment for refractory BPS/IC.
Pinto
Rui
R
Department of Urology, Hospital de São João, Portugal.
Lopes
Tiago
T
Frias
Bárbara
B
Silva
André
A
Silva
João Alturas
JA
Silva
Carlos Martins
CM
Cruz
Célia
C
Cruz
Francisco
F
Dinis
Paulo
P
D000283:Administration, Intravesical; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D018856:Cystitis, Interstitial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A